Articul8

Articul8, developed by Intel and DigitalBridge Group Inc., uses GenAI to turn private data into useful information, accelerating digital transformation across various industries. The company offers a full-stack GenAI platform that delivers AI capabilities that keep customer data, training, and inference within the enterprise's security perimeter, providing customers the choice of cloud, on-premise, or hybrid deployment options. Articul8's GenAI platform is designed to deliver speed, security, and cost-efficiency to help large enterprises operationalize and scale AI. The platform supports a range of hybrid infrastructure alternatives and was initially optimized for Intel's Xeon Scalable processors and Gaudi accelerators.

The platform, developed in collaboration with Boston Consulting Group, uses Intel's supercomputer hardware to offer a GenAI foundation model capable of understanding extensive multi-page documents. It caters to enterprise customers in industry segments requiring high levels of security and specialized domain knowledge, including financial services, aerospace, semiconductors, and telecommunications.

Key customers and partnerships

As of May 2024, Articul8s’ clients included Uptycs and Scripps Health. Uptycs, a provider of security across laptop and the cloud, used Articul8 to perform threat analysis using natural language to generate insights and mitigation techniques. Scripps Health explored its use in medical research and education.

Funding and financials

DigitalBridge Ventures served as lead investor of Articul8. Intel, Fin Capital, Mindset Ventures, Communitas Capital, GiantLeap Capital, GS Futures, and Zain Group have also taken an equity stake in the company.